Akebia Therapeutics公司AKB-097将于2026年下半年启动针对罕见肾脏疾病的II期篮子试验

美股速递04-13

Akebia Therapeutics公司近日宣布，其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性，标志着公司在肾脏疾病治疗领域的重要进展。

篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果，有望加速罕见病治疗方案的开发进程。此次试验的推进，将为进一步验证AKB-097的临床潜力提供关键数据支持。

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/1182427273?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-04-13 20:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1182427273","market":"us","top_or_hot":-1,"title":"Akebia Therapeutics公司AKB-097将于2026年下半年启动针对罕见肾脏疾病的II期篮子试验","media":"美股速递","content":"<p>Akebia Therapeutics公司近日宣布，其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性，标志着公司在肾脏疾病治疗领域的重要进展。</p>\n<p>篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果，有望加速罕见病治疗方案的开发进程。此次试验的推进，将为进一步验证AKB-097的临床潜力提供关键数据支持。</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Akebia Therapeutics公司AKB-097将于2026年下半年启动针对罕见肾脏疾病的II期篮子试验</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAkebia Therapeutics公司AKB-097将于2026年下半年启动针对罕见肾脏疾病的II期篮子试验\n</h2>\n\n<h4 class=\"meta\">\n\n2026-04-13 20:05 北京时间&nbsp;&nbsp;&nbsp;<strong>美股速递</strong>\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Akebia Therapeutics公司近日宣布，其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性，标志着公司在肾脏疾病治疗领域的重要进展。\n篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果，有望加速罕见病治疗方案的开发进程。此次试验的推进，将为进一步验证AKB-097的临床...</p>\n\n<a href=\"\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"AKBA","symbol_name":"Akebia Therapeutics, Inc.","start_time":0,"source_url":"","article_id":"1182427273","we_media_id":"1004306016","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1182427273","pubTimestamp":1776081936,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"美股速递","introduction":"全球快讯第一时间播报","home_visible":1,"id":"1004306016","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"Akebia Therapeutics公司近日宣布，其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性，标志着公司在肾脏疾病治疗领域的重要进展。\n篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果，有望加速罕见病治疗方案的开发进程。此次试验的推进，将为进一步验证AKB-097的临床潜力提供关键数据支持。","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"zh","relate_stocks":{"AKBA":"Akebia Therapeutics, Inc.","BK4139":"生物科技"},"translate_title":"Akebia Therapeutics' AKB-097 will launch a Phase II basket trial for rare kidney disease in the second half of 2026","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"AKBA":1},"content_text":"Akebia Therapeutics公司近日宣布，其研发药物AKB-097计划于2026年下半年进入针对罕见肾脏疾病的II期篮子试验阶段。该试验旨在评估AKB-097在多种罕见肾病患者群体中的疗效与安全性，标志着公司在肾脏疾病治疗领域的重要进展。\n篮子试验设计允许在同一试验框架下同时研究药物对多种疾病亚型的效果，有望加速罕见病治疗方案的开发进程。此次试验的推进，将为进一步验证AKB-097的临床潜力提供关键数据支持。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":true,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1182427273","isCrawlerRequest":true}